RCS - Immupharma PLC - Investor Presentation - Investor Meet Company

ImmuPharmaAnnouncement

04/08/2022 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220804:nRSD8348Ua&default-theme=true

RNS Number : 8348U  Immupharma PLC  04 August 2022

 

 

 

RNS
REACH
4 August 2022

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

INVESTOR PRESENTATION

Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022

 

ImmuPharma is pleased to announce that Tim McCarthy, CEO and Tim Franklin,
COO, will provide a live investor presentation via the Investor Meet Company
platform today, 4 August 2022 at 12:00pm BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am today or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to
meet IMMUPHARMA PLC via:

https://www.investormeetcompany.com/immupharma-plc/register-investor
(https://protect-eu.mimecast.com/s/y8BuCYQw9u5npi0oEaE?domain=investormeetcompany.com)

Investors who already follow IMMUPHARMA PLC on the Investor Meet Company
platform will automatically be invited.

 

Ends

 

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )        +44 (0) 207 206 2650

 Tim McCarthy, Chairman and Chief Executive Officer
 Lisa Baderoon, Head of Investor Relations & Non-Executive Director      + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                                 +44 (0) 203 368 3550 (about%3Ablank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                                +44 (0) 20 3650 3650

 Patrick Claridge, John Howes, Bob Pountney

 SI Capital (Joint Broker)                                               +44 (0) 1483 413500

 Nick Emerson

 

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy
immunomodulator for the treatment of Lupus and preclinical analysis suggest
therapeutic activity for many other autoimmune diseases that share the same
autophagy mechanism of action.

 

The new international Phase 3 trial for Lupuzor™ is being funded by Avion,
who have the exclusive rights to commercialise Lupuzor™ in the US. The rest
of the world rights remain with ImmuPharma and partnering discussions will be
an integral part of creating further opportunities for Lupuzor™ in Lupus and
the P140 platform across several additional indication targets going forward.
The next indication being Chronic inflammatory demyelinating
polyneuropathy (CIDP)

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

About Lupus (Systemic Lupus Erythematosus / SLE)
Lupus is a chronic inflammatory disease which is thought to affect some 5
million individuals worldwide. The current standard of care still consists of
drugs which have many side-effects and limited efficacy. Despite the need for
an effective treatment, only two therapies, namely GlaxoSmithKline's Benlysta
and more recently, Astra Zeneca's Saphnelo, have been approved to treat the
condition over the past 50 years. As such, there clearly exists an unmet
medical need for a drug that has a strong efficacy and safety profile.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEASPDESPAEFA